225 related articles for article (PubMed ID: 28876506)
1. Bisphosphonate therapy and osteogenesis imperfecta: The lived experience of children and their mothers.
Wiggins S; Kreikemeier R
J Spec Pediatr Nurs; 2017 Oct; 22(4):. PubMed ID: 28876506
[TBL] [Abstract][Full Text] [Related]
2. Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta.
Garganta MD; Jaser SS; Lazow MA; Schoenecker JG; Cobry E; Hays SR; Simmons JH
BMC Musculoskelet Disord; 2018 Sep; 19(1):344. PubMed ID: 30249227
[TBL] [Abstract][Full Text] [Related]
3. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle.
Tsimicalis A; Boitor M; Ferland CE; Rauch F; Le May S; Carrier JI; Ngheim T; Bilodeau C
Eur J Pediatr; 2018 Jun; 177(6):891-902. PubMed ID: 29637375
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
7. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
Biggin A; Munns CF
Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
[TBL] [Abstract][Full Text] [Related]
9. Therapy with pamidronate in children with osteogenesis imperfecta.
Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
[TBL] [Abstract][Full Text] [Related]
10. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
12. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate therapy for osteogenesis imperfecta.
Phillipi CA; Remmington T; Steiner RD
Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
[TBL] [Abstract][Full Text] [Related]
14. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
16. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
[TBL] [Abstract][Full Text] [Related]
17. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).
Landsmeer-Beker EA; Massa GG; Maaswinkel-Mooy PD; van de Kamp JJ; Papapoulos SE
Eur J Pediatr; 1997 Oct; 156(10):792-4. PubMed ID: 9365071
[TBL] [Abstract][Full Text] [Related]
18. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.
Trejo P; Rauch F
Osteoporos Int; 2016 Dec; 27(12):3427-3437. PubMed ID: 27492436
[TBL] [Abstract][Full Text] [Related]
19. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
20. Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.
Trejo P; Fassier F; Glorieux FH; Rauch F
J Bone Miner Res; 2017 May; 32(5):1034-1039. PubMed ID: 28019684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
